The perceived risks and benefits of quitting in smokers diagnosed with severe mental illness participating in a smoking cessation intervention / Sacha,L. Filia (2014)  

Public Titre : The perceived risks and benefits of quitting in smokers diagnosed with severe mental illness participating in a smoking cessation intervention : Gender differences and comparison to smokers without mental illness Type de document : document électronique Auteurs : Sacha,L. Filia, Auteur ; Amanda, L. Baker, Auteur ; Caroline, T. Gurvich, Auteur Editeur : Wiley Année de publication : 2014 Collection : Drug and Alcohol Review, ISSN 1465-3362 Importance : p. 78-85 Présentation : tab. Langues : Anglais (eng) Catégories : [DIVERS] géographie:Océanie:Australie [TABAC] étude:épidémiologie [TABAC] prévention:santé:santé mentale [TABAC] sevrage tabagique:effet du sevrage:bénéfice du sevrage tabagique [TABAC] tabagisme:effet du tabac:effet psychiatrique [TABAC] tabagisme:risque:perception du risque Index. décimale : TA 6.10 Conséquences / effets à long-terme du sevrage Résumé : Introduction and Aims. This study aimed to examine the perceived risks and benefits of quitting in smokers diagnosed with psychosis, including potential gender differences and comparisons to smokers in the general population. Design and Methods. Data were collected from 200 people diagnosed with psychosis participating in a randomised controlled trial testing the effectiveness of a multi-component intervention for smoking cessation and cardiovascular disease risk reduction in people with severe mental illness. Results were compared with both treatment and non-treatment seeking smokers in the general population. Results. Male and female smokers with psychosis generally had similar perceived risks and benefits of quitting. Females rated it significantly more likely that they would experience weight gain and negative affect upon quitting than males diagnosed with psychosis. Compared with smokers in the general population also seeking smoking cessation treatment, this sample of smokers with psychosis demonstrated fewer gender differences and lower ratings of perceived risks and benefits of quitting. The pattern of risk and benefit ratings in smokers diagnosed with psychosis was similar to those of non-treatment seeking smokers in the general population. Discussion and Conclusions. These results increase our understanding of smoking in people with severe mental illness, and can directly inform smoking interventions to maximise successful abstinence for this group of smokers.For female smokers with psychosis, smoking cessation interventions need to address concerns regarding weight gain and negative affect. Intervention strategies aimed at enhancing beliefs about the benefits of quitting smoking for both male and female smokers with psychosis are necessary. [Filia S L, Baker A L, Gurvich C T, Richmond R, Kulkarni J. The perceived risks and benefits of quitting in smokers diagnosed with severe mental illness participating in a smoking cessation intervention: Gender differences and comparison to smokers without mental illness. En ligne : https://doi.org/10.1111/dar.12091 Format de la ressource électronique : PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9552

Aucun avis, veuillez vous identifier pour ajouter le vôtre !

Tobacco use discorder and dual disorders / Néstor Szerman (2022)  

Public Titre : Tobacco use discorder and dual disorders : Joint statement by the Spanish Psychiatry Society and the Spanish Dual Disorders Society Type de document : document électronique Auteurs : Néstor Szerman, Auteur ; Carlos Parro, Auteur ; Cristina Pinet, Auteur ; José Martínez-Raga, Auteur Editeur : Madrid [Espagne] : María I. López-Ibor Année de publication : 2022 Collection : Actas Españolas de Psiquiatría Importance : p. 77-138 Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique [TABAC] tabagisme:effet du tabac:effet bénéfique du tabac [TABAC] tabagisme:effet du tabac:effet psychiatrique Index. décimale : TA 3.2 Effets du tabagisme actif Résumé : Tobacco Use Disorder (TUD) is a health problem of the first order in the world population, affecting a vulnerable population, such as people with other mental disorders, whose morbidity and mortality are increased as a result. The high prevalence of TUD in people with other mental disorders is fundamentally related to common, genetic and neurobiological factors linked to the cerebral nicotinic cholinergic system involved in mental functioning, health and disease. Patients with mental disorders may find an improvement in their mental functioning at a cognitive and emotional level due to the nicotine released when using tobacco, with positive effects on neurocognition, mood, anxiety and certain pathological traits. Difficulties in achieving tobacco abstinence, a desirable goal, are evident in a very large proportion of patients, so realistic goals must be proposed to ensure a reduction in harm. The different pharmacological treatment strategies are not fully effective and need to be administered for prolonged periods of time, as with other psychoactive drugs. Varenicline would be the first pharmacological option, followed by bupropion or both combined, as they have different mechanisms of action. In this therapeutic approach, treatment with nicotine replacement agonists in their different forms (e.g. patches, gum or spray) at adequate doses and other unregulated nicotine release devices, such as electronic cigarettes, snus and heat-not-burn products should be considered. As future prospects, the diagnosis of TUD should gain greater importance so that patients with other mental disorders, dual disorders, can receive appropriate multidisciplinary care and integrated treatment to reduce or stop tobacco use entirely. En ligne : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11095114/ Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10247

Aucun avis, veuillez vous identifier pour ajouter le vôtre !